THERAPY OF POST-OPERATIVE NAUSEA AND VOMITING
Amisulpride is useful in the therapy (particularly the prevention of) post-operative nausea and/or vomiting (PONV) in a patient, particularly wherein the patient has a high (≥30) BMI and/or the patient is a bariatric surgery patient.
1 . Amisulpride for use in the therapy of post-operative nausea and/or vomiting in a patient, wherein the patient:
a) has a BMI of equal to or greater than about 30; and/or
b) is a bariatric surgery patient.
2 . Amisulpride for use according to claim 1 , wherein the patient has a BMI of equal to or greater than about 30.
3 . Amisulpride for use according to claim 1 or 2 wherein the patient is a bariatric surgery patient.
4 . Amisulpride for use according to any preceding claim, wherein the patient has a BMI of equal to or greater than about 35.
5 . Amisulpride for use according to any preceding claim, wherein the patient will undergo or is undergoing bariatric surgery, preferably the patient is undergoing bariatric surgery.
6 . Amisulpride for use according to any one of claims 1 to 5 , wherein the therapy is prophylaxis.
7 . Amisulpride for use according to any of claims 1 to 4 , wherein the patient has undergone bariatric surgery.
8 . Amisulpride for use according to any of claims 1 to 4 or 7 , wherein the therapy is treatment, preferably rescue treatment.
9 . Amisulpride for use according to any one of claims 1 to 8 , wherein the patient has already been administered a prophylaxis drug for postoperative nausea and/or vomiting.
10 . Amisulpride for use according to claim 9 , wherein the prophylaxis drug is not amisulpride.
11 . Amisulpride for use according to claim 9 or claim 10 , wherein the prophylaxis drug is not a dopamine-2 (D 2 ) antagonist.
12 . Amisulpride for use according to any one of claims 9 to 11 , wherein the prophylaxis drug is an anti-emetic selected from a 5HT 3 -antagonist, a corticosteroid, an anti-histamine (H 1 ), an anti-cholinergic, a H 2 -antagonist or a NK 1 -antagonist.
13 . Amisulpride for use according to any preceding claim, wherein the amisulpride is administered in combination with another anti-emetic, either separately, sequentially or simultaneously.
14 . Amisulpride for use according to claim 13 , wherein the other anti-emetic is a 5HT 3 antagonist, an NK 1 antagonist or a steroid.
15 . Amisulpride for use according to claim 13 or claim 14 , wherein the other anti-emetic is dexamethasone, ondansetron, granisetron, palonosetron, aprepitant, netupitant or rolapitant.
16 . Amisulpride for use according to any one of claims 1 to 15 , wherein the amisulpride is substantially in the form of a racemate.
17 . Amisulpride for use according to any one of claims 1 to 16 , wherein the amisulpride is in the form of (S−)-amisulpride, which is substantially free of the (R+)-enantiomer.
18 . Amisulpride for use according to any one of claims 1 to 17 , wherein the amisulpride is administered via the intravenous route.
19 . Amisulpride for use according to any one of claims 1 to 18 , wherein the amisulpride is administered by IV infusion over from about 1 to about 2 minutes.
20 . Amisulpride for use according to any one of claims 1 to 19 , wherein the amisulpride is administered in a single dose.
21 . Amisulpride for use according to any one of claims 1 to 20 , wherein the amisulpride is administered at the time of induction of anaesthesia.
22 . Amisulpride for use according to any one of one of claims 1 to 21 , wherein the patient is human.
23 . Amisulpride for use according to any one of one of claims 1 to 22 , wherein the dose of amisulpride is from about 1 to about 40 mg.
24 . Amisulpride for use according to any one of claims 1 to 23 , wherein the dose of amisulpride is about 1 to about 20 mg.
25 . Amisulpride for use according to any one of one of claims 1 to 24 , wherein the dose of amisulpride is 5 to 15 mg.
26 . Amisulpride for use according to any one of one of claims 1 to 25 , wherein the dose of amisulpride is about 7.5 mg to 15 mg, preferably about 10 mg.
27 . Amisulpride for use according to any one of one of claims 1 to 25 , wherein the dose of amisulpride is about 5 mg.
28 . A method of therapy of post-operative nausea and/or vomiting in a patient, wherein the patient:
(a) has a BMI of equal to or greater than about 30 (i.e. ≥about 30); and/or
(b) is a bariatric surgery patient;
said method comprising administration of an effective amount of a compound of amisulpride to the patient.
29 . The method according to claim 28 , having any of the additional features of claims 2 to 27 .
30 . Use of amisulpride, for the manufacture of a medicament for the therapy of post-operative nausea and/or vomiting in a patient, wherein the patient:
(a) has a BMI of equal to or greater than about 30 (i.e. ≥about 30); and/or
(b) is a bariatric surgery patient.
31 . The use according to claim 30 , having any of the additional features of claims 2 to 27 .